Akèy › Polineyropati
Etid klinik pou Polineyropati ap rekrite nan Etazini
6 etid pou Polineyropati ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Baltimore, MD4 etid
- Philadelphia, PA4 etid
- Durham, NC4 etid
- New York City, NY4 etid
- Los Angeles, CA3 etid
- Houston, TX3 etid
- San Diego, CA3 etid
- Boston, MA3 etid
- Dallas, TX3 etid
- Chicago, IL3 etid
- Rochester, MN3 etid
Pa eta
- Illinois3 etid
- Kalifòni3 etid
- Maryland4 etid
- Massachusetts3 etid
- Minnesota3 etid
- New York4 etid
- North Carolina4 etid
- Pennsylvania4 etid
- Texas4 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
Ap rekriteEtid obsèvasyon
Laj 18 a 130 · Tout sèks · Mizajou Sep 23, 2026 · NCT06465810TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
Ap rekriteFaz 3
Laj 18 a 85 · Tout sèks · Mizajou Sep 15, 2026 · NCT07223203ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Sep 8, 2026 · NCT04561518Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program
Ap rekriteEtid obsèvasyon
Tout laj · Fanm · Mizajou Sep 8, 2026 · NCT05040373Using the EHR to Advance Genomic Medicine Across a Diverse Health System
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Aug 14, 2026 · NCT06377033Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Ap rekriteFaz 3
Laj 18 a 75 · Tout sèks · Mizajou Aug 4, 2026 · NCT06563895Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.